Results 101 to 110 of about 3,242 (120)

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma

Journal of Hepatology, 2022
Jian Gao, Jia Fan, Jian Zhou
exaly  

Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy

ACS Nano, 2022
Liping Qiu, Xiaohong Fang, Yu Yang
exaly  

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

Acta Biomaterialia, 2021
Xuefei Zhang, Na Shen, Xuesi Chen
exaly  

A Pd1–Ps–P1 Feedback Loop Controls Pubescence Density in Soybean

Molecular Plant, 2020
Zhixi Tian, Muhammad Imran, Shulin Liu   +2 more
exaly  

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

International Journal of Molecular Sciences, 2021
Luc Thiberville, Nicolas Piton, Florian Guisier   +2 more
exaly  

BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse

Cell Stem Cell, 2020
Cun-Yu Wang
exaly  

The impact of corticosteroid use during anti-PD1 treatment

Journal of Oncology Pharmacy Practice, 2020
Yifang Eva Pan
exaly  

Biotransformation of cadinane sesquiterpenes by Beauveria bassiana ATCC 7159

Phytochemistry, 2000
Paul B Reese, Lawrence A D Williams
exaly  

Biotransformation of diterpenes and diterpene derivatives by Beauveria bassiana ATCC 7159

Phytochemistry, 2001
Paul B Reese
exaly  

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

Investigational New Drugs, 2008
Lesley Seymour, Timothy Synold, Sharlene Gill   +2 more
exaly